Free Trial
→ Musk’s Next $4 Trillion Takeover Target – It’s Stranger than you Think (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:RZLT

Rezolute Q3 2024 Earnings Report

Rezolute logo
$3.28 +0.11 (+3.31%)
As of 12:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Rezolute EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.34
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Rezolute Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rezolute Announcement Details

Quarter
Q3 2024
Date
5/15/2024
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Rezolute's Q3 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Rezolute's Q3 2024 Press ReleasePress Release
(8-K)
Rezolute's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Rezolute Earnings Headlines

Rezolute to Participate in Upcoming Investor Conferences
May 11 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/11/3291727/0/en/rezolute-to-participate-in-upcoming-investor-conferences.html
Rezolute (RZLT) Expected to Announce Quarterly Earnings on Tuesday
May 10 at 3:55 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30769264
Your book attached
Bill Poulos is offering a temporary backdoor link that skips the order page for his Simple Options Trading For Beginners guide - normally $29.97 on his website. No cart, no checkout. The link goes straight to the download page at no cost. Once it expires, the full price applies.tc pixel
May 12 at 1:00 AM  |  Profits Run (Ad)
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society ...
May 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-annual-meeting-1036095326
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
May 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/01/3286124/0/en/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-annual-me.html
Rezolute, Inc. Investigated by the Portnoy Law Firm
April 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/24/3280797/0/en/rezolute-inc-investigated-by-the-portnoy-law-firm.html
See More Rezolute Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rezolute? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rezolute and other key companies, straight to your email.

About Rezolute

Rezolute (NASDAQ:RZLT), a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

View Rezolute Profile
Earnings Tools